Last checked at 26 Jul 2022 17:35
26 July 2022
Haleon plc
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | Haleon plc | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify): | ||||||
3. Details of person subject to the notification obligation | ||||||
Name | GSK plc | |||||
City and country of registered office (if applicable) | London, England | |||||
4. Full name of shareholder(s) (if different from 3.) | ||||||
Name | Vidacos Nominees Limited | |||||
City and country of registered office (if applicable) | London, England | |||||
5. Date on which the threshold was crossed or reached : | 25 July 2022 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 25/07/2022 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) | |||
Resulting situation on the date on which threshold was crossed or reached | 12.94 | 0 | 12.94 | 1,195,320,110 | ||
Position of previous notification (if applicable) | 12.94 | 0 | 12.94 | |||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rights | % of voting rights | |||||||
Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
GB00BMX86B70 | 0 | 1,195,320,110 | 0 | 12.94 | |||||
SUBTOTAL 8. A | 1,195,320,110 | 12.94 | |||||||
| |||||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expirationdate | Exercise/Conversion Period | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expirationdate | Exercise/Conversion Period | Physical or cash Settlement | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | ||||||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | ||||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) | X | |||
Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
GSK plc (Chain 1) | 5.44 | 5.44 | ||
GlaxoSmithKline Holdings Limited (Chain 1) | 5.44 | 5.44 | ||
GlaxoSmithKline Finance plc (Chain 1) | 5.44 | 5.44 | ||
Glaxo Group Limited (Chain 1) | 5.44 | 5.44 | ||
GSK plc (Chain 2) | 4.74 | 4.74 | ||
GSK LP Limited (Chain 2) | 4.74 | 4.74 | ||
GSK GP 1 Limited (Chain 2) | 4.74 | 4.74 | ||
GSK (No. 1) Scottish Limited Partnership (Chain 2) | 4.74 | 4.74 | ||
GSK plc (Chain 3) | 1.78 | 1.78 | ||
GSK LP Limited (Chain 3) | 1.78 | 1.78 | ||
GSK GP 1 Limited (Chain 3) | 1.78 | 1.78 | ||
GSK (No. 2) Scottish Limited Partnership (Chain 3) | 1.78 | 1.78 | ||
GSK plc (Chain 4) | 0.98 | 0.98 | ||
GSK LP Limited (Chain 4) | 0.98 | 0.98 | ||
GSK GP 2 Limited (Chain 4) | 0.98 | 0.98 | ||
GSK (No. 3) Scottish Limited Partnership (Chain 4) | 0.98 | 0.98 | ||
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional information | ||||
This notification relates to the transfer by GSK plc of its direct retained 5.44% stake in Haleon plc to Glaxo Group Limited (a wholly owned subsidiary of GSK plc and the holder of other external minority interests of the GSK group).
The GSK group's aggregate interest in Haleon plc remains unchanged following the transfer. A separate TR-1 has also been submitted today by GSK plc on behalf of Glaxo Group Limited and Glaxo Group Limited's parent undertakings (other than GSK plc) to satisfy their notification obligations.
Glaxo Group Limited, GSK (No. 1) Scottish Limited Partnership, GSK (No. 2) Scottish Limited Partnership and GSK (No. 3) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.
These calculations are based on an issued share capital of Haleon plc of 9,234,573,831 ordinary shares.
| ||||
Place of completion | London, England |
Date of completion | 25 July 2022 |